Independent drugmaker Norgine is to acquire specialty pharma company Merus Labs International (Nasdaq: MSLI) in a $342 million deal, news of which sent the latter company’s share price spiraling by 54% to $1.19 in Thursday morning’s trading.
Norgine, a leading European specialist pharmaceutical company focusing on gastroenterology, hepatology, cancer and supportive care, had total sales of 295 million euros ($321 million) in 2016, almost three times Merus’ gross basic revenue for the year, which was $111 million.
"Our acquisition of Merus will strengthen our position as the ‘go-to’ European specialist pharma"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze